CathyEngMDFACP, FASCO

Gastrointestinal Cancer, Hematologic Oncology

Vanderbilt-Ingram Cancer Center; David H. Johnson Endowed Chair in Surgical and Medical Oncology; Professor of Medicine, Hematology and Oncology; Director for Strategic Relations; Co-Director, GI Oncology; Co-Leader, Gastrointestinal Cancer Research Program; Director, Young Adult Cancers Program; Co-Chair, NCI GI Steering Committee

Join to view full profile

Dr. Eng is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Eng's full profile

Already have an account?

Office
3601 The Vanderbilt Clinic
Nashville, TN 37232
Phone+1 615-322-3000

Summary

Dr. Cathy Eng is an oncologist in Nashville, TN and is affiliated with Vanderbilt-Ingram Cancer Center. She received her medical degree from Drexel University College of Medicine/Hahnemann University and has been in practice 23 years. She specializes in gastrointestinal cancer clinical research.

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 1999 - 2002
Rush University Medical CenterResidency, Internal Medicine, 1996 - 1999
Rutgers Health/Cooperman Barnabas Medical CenterResidency, Radiology-Diagnostic, 1995 - 1996
Drexel University College of Medicine/Hahnemann University HospitalInternship, Internal Medicine, 1994 - 1995
Drexel University College of MedicineClass of 1994

Certifications & Licensure

IL State Medical License 1998 - 2026
TX State Medical License 2002 - 2026
TN State Medical License 2019 - 2025
AL State Medical License 2020 - 2020
NJ State Medical License 1995 - 1997
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

White House Cancer Moonshot Colorectal Cancer Panel: Colorectal Cancer Treatment, Innovation and support White House, 2023
Fellow Hedwig van Ameringen Executive Leadership in Academic Medicine, 2022
Regional Top Doctor Castle Connolly, 2009-2022
Top Doctor Nashville Lifestyles Magazine, 2000-2022
Exceptional Women in Medicine Castle Connolly, 2019-2021
Fellowship American Society of Clinical Oncology, 2019
Top Doctor in Oncology Houston Magazine, 2019
Join now to see all

Clinical Trials

Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Start of enrollment: 2004 Apr 01
Completed
Phase 2
S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer Start of enrollment: 2006 Nov 01
Withdrawn
Phase 2
Prognostic Molecular and Environmental Factors in High-Risk Colon Cancer Patients Start of enrollment: 2006 Jan 01
Active, not recruiting
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer Start of enrollment: 2010 Jan 26
Completed
Phase 1, Phase 2
Phase II Study of Minocycline for Reducing Symptom Burden in Colorectal Patients Start of enrollment: 2013 Nov 01
Completed
Phase 2
Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2020 Jan 28
Completed
Phase 1
EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients Start of enrollment: 2020 Nov 17
Recruiting
Phase 3
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors Start of enrollment: 2021 Aug 09
Active, not recruiting
Phase 1, Phase 2
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. Start of enrollment: 2021 May 10
Active, not recruiting
Phase 1, Phase 2
A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer Start of enrollment: 2022 Feb 12
Active, not recruiting
Phase 2, Phase 3
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer Start of enrollment: 2015 May 13
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Results of the phase I/II study and preliminary B cell gene signature of combined inhibition of glutamine metabolism and EGFR in colorectal cancer.
Kristen K Ciombor, Seong-Woo Bae, Jennifer G Whisenant, Gregory D Ayers, Quanhu Sheng
Clinical Cancer Research. 2025-02-10
1 citations
Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline.
Van K Morris, Erin B Kennedy, Manik A Amin, Olivia Aranha, Al B Benson 3rd
Journal of Clinical Oncology. 2025-02-10
Moving towards more personalized approaches in locally advanced and metastatic colorectal cancer.
Chelsie K Sievers, Cathy Eng
Nature Reviews. Gastroenterology & Hepatology. 2025-02-01

Journal Articles

Spectrum of Somatic Cancer Gene Variations Among Adults with Appendiceal Cancer by Age at Disease Onset
Cathy Eng, MD, JAMA Network Open

Lectures

The Long-Term Impact of Neurofeedback on Symptom Burden and Interference in Patients with Chronic Chemotherapy-Induced Neuropathy: Analysis of a Randomized Controlled ...
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019

Press Mentions

Experts Publish Action Plan to Address Appendiceal Cancer EnigmasFebruary 20th, 2025
The Race to Explain Why More Young Adults Are Getting CancerFebruary 13th, 2025
Only Half of Young Cancer Patients Report a Discussion on Fertility PreservationNovember 12th, 2024
Join now to see all